Toggle Nav
Close
  • Menu
  • Setting

Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE)

Catalog No.
F1465
Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE)
Grouped product items
SizePriceStock Qty
100ug
Please inquire
Ship with 3-5 days
1mg
Please inquire
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Andecaliximab is a biopharmaceutical targeting matrix metalloproteinase 9 (Andecaliximab is a recombinant IgG4 monoclonal antibody against MMP9. Andecaliximab has shown anti-fibrotic efficacy in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used in the study of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

145 kDa

Shipping

Dry ice

Cas No.

1518996-49-0

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

AB0045, GS-5745

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

P20273

Reactivity

Human

Conjugation

MMAE

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG4

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Biological Activity

Human Siglec-2 / CD22 HEK293 Cell Line were stained with Anti-Siglec-2/CD22 Antibody (Inotuzumab-MMAE) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.16 μg/mL.

Target

Siglec-2 / CD22

Note

Please avoid freeze-thaw cycles.